Close Menu

Becton Dickinson

The firm raised its full fiscal year 2018 revenue and adjusted earnings per share guidance.

Enzo Biochem and its subsidiary Enzo Life Sciences announced this week that the Patent Trial and Appeal Board has denied a petition filed by Hologic for inter partes review, a procedure for challenging the validity of patent claims, against US Patent 6,221,581.

The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.

One outcome of a recent FDA workshop about the potential for using self-collection for Pap testing was that it might be better to do self-collection in combination with molecular testing.

The agency cleared two Roche tests that run on its Cobas systems. One does Chlamydia trachomatis and Neisseria gonorrhoeae testing and the other does hematology testing.

A brief recap of Diagnostics news the week of Ma4r 23, 2018: Bruker, T2 Biosystems, Philips, Meridian Bioscience, Agilent, Biotechnology Industry Research Assistance Council, Becton Dickinson, Strata Oncology.

BD and the FDA said that a chemical called thiuram found in certain BD blood collection tubes may render results from Magellan's LeadCare blood lead tests inaccurate.

Among companies whose tests were greenlighted by the FDA last month, Quidel received clearances for a test to detect and differentiate influenza types A and B, and for a separate test for Lyme disease.

The PAXgene Blood ccfDNA tube enables clinical laboratories to stabilize samples when they cannot be processed on the day they were collected.

BD alleges Cytek hired away former BD employees to develop flow cytometry products to compete against BD.

Pages